Curt R. Hartman is the seasoned President and CEO of CONMED Corporation, a leading player in the medical device space. He stepped into his current role in November 2014 after serving as the Interim CEO a few months prior. Before...

Curt R. Hartman is the seasoned President and CEO of CONMED Corporation, a leading player in the medical device space. He stepped into his current role in November 2014 after serving as the Interim CEO a few months prior. Before joining CONMED, Hartman spent over two decades at Stryker Corporation, where he had a hand in various leadership positions, including CFO and Interim CEO. His educational background includes a degree in Aerospace Engineering from the University of Michigan and an advanced management program certificate from Harvard. This blend of technical and financial expertise gives him a unique view on running a medical device company. Under his leadership, CONMED is focusing on innovation and aligning its goals with shareholder interests. His recent compensation package reflects this systematic approach, showcasing a total of approximately $4.59 million in 2018, with a significant portion tied to performance metrics. Hartman's career has been marked by strategic roles that influenced growth and operational effectiveness, which positions him as a driving force in the healthcare industry. He is particularly known for pushing CONMED to integrate new technologies and improving overall company performance while keeping a keen eye on sustainability practices and social responsibility.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other CONMED CEOs

C

Curt R. Hartman

Ex-CEO of CONMED

Education

Bachelor of Science degree in Aerospace Engineering from the University of Michigan

Field of Expertise

Technology & Engineering - Engineering

Sector of Economy

Healthcare

Born

January 1, 1964 - 61 years ago

CEO of CONMED for

10 years 5 months (Jul 2014 - Jan 2025)

Previous Experience

Interim Chief Executive Officer of Stryker

Rivals

Competitors/colleagues of Curt R. Hartman

M

Fred P. Lampropoulos

Founder and CEO of Merit Medical Systems

2023 Compensation

Stock

$2.77M

Salary

$1.89M

Bonus

$1.34M

Other

$8.70K

Total Holdings

$135.21M

Holdings

See how much did Curt R. Hartman make over time.

Curt R. Hartman has seen some significant fluctuations in his holdings tied to CONMED Corporation. Over the years, his equity stake has varied, reflecting the company's performance. As of 2018, he had accrued approximately 1.3 million options, which hold substantial...

Curt R. Hartman has seen some significant fluctuations in his holdings tied to CONMED Corporation. Over the years, his equity stake has varied, reflecting the company's performance. As of 2018, he had accrued approximately 1.3 million options, which hold substantial value given the company's growth trajectory. This shows how Hartman’s wealth is closely linked to CONMED's market performance, making his interests closely aligned with those of shareholders. In 2016, he mostly held his wealth in CONMED, riding with the company during its growth phases. As events unfolded, this percentage fluctuated but still represents a significant portion of his net worth, indicating his commitment to the company. His focus has been on improving shareholder value, evidenced by his historical investment in CONMED during critical growth times.

Total Stock Sold

$12.13M

CNMD

$11.92M

94,877 CNMD shares

SYK

$208.92K

3,300 SYK shares

What if they kept their stock?

If Curt R. Hartman didn't sell their stock, today they would have:
Extra CNMD94,877 shares worth $6.82M and SYK3,300 shares worth $567.86K.
This is -39.11% and $4.74M less than what they got when they sold the stock.

Charitable Transactions

CNMD

89,000 shares

CNMD

Recent Charitable Transactions

CNMD

89,000 shares

CNMD

Sep 15, 2021

Charity

Insider Trading

See recent insider trades of Curt R. Hartman.

CNMD

$136.00K

CNMD at $136.00/share

Jun 15, 2023

Sale

CNMD

$464.03K

CNMD at $92.81/share

Mar 14, 2023

Sale

CNMD

$328.78K

CNMD at $93.94/share

Sep 15, 2022

Sale

CNMD

$346.07K

CNMD at $138.43/share

Mar 15, 2022

Sale

CNMD

89,000 shares

CNMD

Sep 15, 2021

Charity

CNMD

89,000 shares

CNMD

Sep 15, 2021

Charity

CNMD

$318.47K

CNMD at $127.39/share

Sep 15, 2021

Sale

CNMD

$5.59M

CNMD at $132.09/share

Jun 3, 2021

Sale

CNMD

$1.86M

CNMD at $142.87/share

May 14, 2021

Sale

CNMD

$1.80M

CNMD at $120.21/share

Feb 18, 2021

Sale

Compensation History

See how much did Curt R. Hartman make over time.

Curt R. Hartman's compensation strategy illustrates a high-performance focus. In 2018, he earned a total compensation of $4.59 million, with $790,917 as salary and $2,618,000 from stock options. However, he did not receive any bonuses or stock grants in that year, indicating that his pay is deeply tied to long-term incentives rather than short-term results. This aligns with CONMED's culture of rewarding executives based on performance metrics, focusing on growth and sustainability. In the years leading up to 2018, his total compensation showed a trend of growth, especially prominent when recognizing the strategic achievements during his tenure. The absence of short-term bonuses showcases a commitment to long-term performance, which has been his strategy to ensure the company thrives and adapts in an ever-changing industry landscape.

Year

2018

Total Compensation

$893.32K

Salary

$790.92K

Board Justification

The company's compensation philosophy is designed to attract, retain, and motivate top talent while aligning executive compensation with the company's performance and shareholder interests.

Bonus

$0.00

Board Justification

No bonus was awarded for the year 2018 as per the proxy statement.

Other

$102.40K

Board Justification

Other compensation includes contributions to retirement plans and other benefits.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock awards were vested in 2018 as per the proxy statement.

Performance Metrics

The performance metrics for the CEO's compensation are based on the company's financial performance, including sales growth and adjusted earnings per share.

Other CONMED CEOs

Here are other CEOs of CONMED

Joseph J. Corasanti

Ex-CEO of CONMED

January 2007 - July 2014

Pat Beyer

CEO of CONMED

January 2025 - Present